comparemela.com

Latest Breaking News On - Myovant sciences ltd - Page 27 : comparemela.com

Pfizer, Inc (NYSE:PFE), (MYOV) - Myovant - Pfizer s Uterine Fibroids Treatment Wins FDA Approval

Pfizer, Inc (NYSE:PFE), (MYOV) - Myovant - Pfizer s Uterine Fibroids Treatment Wins FDA Approval
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

(MYOV) - Myovant Stock Is Trading Lower After FDA Slapped Clinical Hold On Relugolix Combo Study

(MYOV) - Myovant Stock Is Trading Lower After FDA Slapped Clinical Hold On Relugolix Combo Study
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Myovant Sciences Says FDA Places Phase 3 SERENE Study On Partial Clinical Hold

NEW YORK CITY (dpa-AFX) - Myovant Sciences Ltd. (MYOV) said the Food and Drug Administration has placed a partial clinical hold on the Phase 3 SERENE study of its relugolix combination tablet proposed

Progressive, Iovance fall; Target, Take-Two rise

Progressive, Iovance fall; Target, Take-Two rise by The Associated Press Last Updated May 19, 2021 at 4:27 pm EDT NEW YORK (AP) Target Corp., up $12.58 to $219.01. The retailer blew away Wall Street’s first-quarter profit and revenue forecasts. Take-Two Interactive Software Inc., up $11.66 to $179.35. The publisher of “Grand Theft Auto” and other video games reported strong fiscal fourth-quarter financial results. Tesla Inc., down $14.41 to $563.46. The electric vehicle maker’s sales in China reportedly slumped in April. Progressive Corp., down $4.98 to $101. The insurance company’s first-quarter profit fell short of Wall Street forecasts. Iovance Biotherapeutics Inc., down $10.64 to $16.33. The biotechnology company expects to ask for regulatory approval of its lifileucel cancer therapy in the first half of 2022.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.